Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)

被引：22

作者：

Gay, Francesca ^{[1
]}

Cerrato, Chiara ^{[1
]}

Scalabrini, Delia Rota ^{[1
]}

Galli, Monica ^{[1
]}

Belotti, Angelo ^{[1
]}

Zamagni, Elena ^{[1
]}

Ledda, Antonio ^{[1
]}

Grasso, Mariella ^{[1
]}

Angelucci, Emanuele ^{[1
]}

Liberati, Anna Marina ^{[1
]}

Tosi, Patrizia ^{[1
]}

Pisani, Francesco ^{[1
]}

Spada, Stefano ^{[1
]}

Annibali, Ombretta ^{[1
]}

Baraldi, Anna ^{[1
]}

Omede, Paola ^{[1
]}

Galieni, Piero ^{[1
]}

Rizzi, Rita ^{[1
]}

Pescosta, Norbert ^{[1
]}

Ronconi, Sonia ^{[1
]}

Vincelli, Donatella ^{[1
]}

Cafro, Anna Maria ^{[1
]}

Offidani, Massimo ^{[1
]}

Palumbo, Antonio ^{[2
,3
]}

Musto, Pellegrino ^{[1
]}

Cavo, Michele ^{[1
]}

Boccadoro, Mario ^{[1
]}

机构：

[1] European Myeloma Network, GIMEMA, Milan, Italy

[2] Univ Torino, Turin, Italy

[3] Takeda Pharmaceut Co, Zurich, Switzerland

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-112093

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

121

引用

页数：4

共 50 条

[41] Carfilzomib-lenalidomide-dexamethasone Vs. lenalidomide-dexamethasone in non-frail transplant-ineligible patients with newly diagnosed multiple myeloma: the EMN20 trial [J].

D'Agostino, Mattia ;

Antonioli, Elisabetta ;

Gamberi, Barbara ;

Bruno, Benedetto ;

Derudas, Daniele ;

Tosi, Patrizia ;

Fazio, Francesca ;

Carlo-Stella, Carmelo ;

Ronconi, Sonia ;

Corradini, Paolo ;

Ballanti, Stelvio ;

Cellini, Claudia ;

Falcone, Antonietta Pia ;

Bringhen, Sara ;

Offidani, Massimo ;

Rambaldi, Alessandro ;

Rota-Scalabrini, Delia ;

Agazzi, Alberto ;

Casaluci, Gloria Margiotta ;

Pietrantuono, Giuseppe ;

Patriarca, Francesca ;

Larocca, Alessandra ;

Boccadoro, Mario .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 :S94-S95

[42] Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD) [J].

Bringhen, Sara ;

Antonioli, Elisabetta ;

Gamberi, Barbara ;

Bruno, Benedetto ;

Derudas, Daniele ;

Tosi, Patrizia ;

Fazio, Francesca ;

Mazza, Rita ;

Ronconi, Sonia ;

Corradini, Paolo ;

Lotti, Flavia ;

Cellini, Claudia ;

Falcone, Antonietta Pia ;

Galieni, Piero ;

Ria, Roberto ;

Belotti, Angelo ;

Mannina, Donato ;

Cafro, Anna Maria ;

Cangialosi, Clotilde ;

Vincelli, Iolanda Donatella ;

Lombardo, Alessandra ;

Larocca, Alessandra ;

Boccadoro, Mario ;

D'Agostino, Mattia .

BLOOD, 2023, 142

[43] Planned Interim Analysis of the GMMG-CONCEPT Trial investigating Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma [J].

Leypoldt, L. ;

Besemer, B. ;

Haenel, M. ;

Raab, M. -S ;

Mann, C. ;

Munder, M. ;

Reinhardt, H. C. ;

Nogai, A. ;

Goerner, M. ;

Ko, Y. -D ;

de Wit, M. ;

Salwender, H. ;

Scheid, C. ;

Graeven, U. ;

Peceny, R. ;

Staib, P. ;

Dieing, A. ;

Einsele, H. ;

Jauch, A. ;

Zago, M. ;

Benner, A. ;

Tichy, D. ;

Bokemeyer, C. ;

Goldschmidt, H. ;

Weisel, K. .

ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 :55-56

[44] Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). [J].

Zimmerman, Todd M. ;

Griffith, Kent A. ;

Jasielec, Jagoda ;

Rosenbaum, Cara Ann ;

McDonnell, Kathryn ;

Waite-Marin, Jessica ;

Berdeja, Jesus G. ;

Raje, Noopur S. ;

Reece, Donna Ellen ;

Vij, Ravi ;

Alonge, Mattina ;

Rosebeck, Shaun ;

Gurbuxani, Sandeep ;

Faham, Malek ;

Kong, Katherine A. ;

Levy, Joan ;

Jakubowiak, Andrzej J. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[45] Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial [J].

Wester, Ruth ;

van der Holt, Bronno ;

Asselbergs, Emelie ;

Zweegman, Sonja ;

Kersten, Marie Jose ;

Vellenga, Edo ;

Kooij, Marinus van Marwijk ;

de Weerdt, Okke ;

Minnema, Monique C. ;

Lonergan, Sarah ;

Palumbo, Antonio ;

Lokhorst, Henk M. ;

Broyl, Annemiek ;

Iskander, Karim Saad ;

Sonneveld, Pieter .

BLOOD, 2017, 130

[46] GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years [J].

Mateos, Maria-Victoria ;

Paiva, Bruno ;

Cedena Romero, Maria Teresa ;

Puig, Noemi ;

Sureda Balari, Anna Maria ;

Oriol, Albert ;

Ocio, Enrique M. ;

Rosinol, Laura ;

Gonzalez-Montes, Yolanda ;

Jose Bargay, Juan ;

Gonzalez Garcia, Esther ;

Hernandez Garcia, Miguel Teodoro ;

Ramirez, Angel ;

Suarez-Cabrera, Alexia ;

Blanchard, Maria-Jesus ;

Garzon, Sebastian ;

Casado Montero, Luis Felipe ;

Cabanas Perianes, Valentin ;

Perez De Oteyza, Jaime ;

Gironella, Mercedes ;

Martinez-Lopez, Joaquin ;

Ana-Isabel-Teruel ;

Delgado, Pilar ;

Prieto, Elena ;

Lahuerta Palacios, Juan Jose ;

Blade, Joan ;

San Miguel, Jesus .

BLOOD, 2023, 142

[47] Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial [J].

Costa, Luciano J. ;

Chhabra, Saurabh ;

Medvedova, Eva ;

Schmidt, Timothy Martin ;

Dholaria, Bhagirathbhai ;

Godby, Kelly N. ;

Silbermann, Rebecca ;

Bal, Susan ;

D'Souza, Anita ;

Giri, Smith ;

Omel, James L. ;

Hari, Parameswaran ;

Callander, Natalie ;

Dhakal, Binod .

BLOOD, 2022, 140 :7275-7277

[48] Depth of response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in front-line induction of high-risk Multiple Myeloma: Interim analysis of the GMMG-CONCEPT trial [J].

Weisel, K. C. ;

Asemissen, A. M. ;

Leypoldt, L. ;

Besemer, B. ;

Haenel, M. ;

Blau, I. W. ;

Goerner, M. ;

Ko, Y. -D. ;

Duerig, J. ;

Staib, P. ;

Mann, C. ;

Lutz, R. ;

Munder, M. ;

Graeven, U. ;

Peceny, R. ;

Salwender, H. ;

Zago, M. ;

Benner, A. ;

Tichy, D. ;

Bokemeyer, C. ;

Goldschmidt, H. .

ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) :91-92

[49] Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial [J].

Wester, Ruth ;

van der Holt, Bronno ;

Asselbergs, Emelie ;

van Duin, Mark ;

Zweegman, Sonja ;

Kersten, Marie Jose ;

Vellenga, Edo ;

Kooy, Marinus van Marwijk ;

de Weerdt, Okke ;

Minnema, Monique ;

Lonergan, Sarah ;

Palumbo, Antonio ;

Lokhorst, Henk M. ;

Broijl, Annemiek ;

Sonneveld, Pieter .

BLOOD, 2016, 128 (22)

[50] Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial [J].

Wester, Ruth ;

van der Holt, Bronno ;

Asselbergs, Emelie ;

Zweegman, Sonja ;

Kersten, Marie Jose ;

Vellenga, Edo ;

Kooy, Marinus van Marwijk ;

de Weerdt, Okke ;

Minnema, Monique ;

Lonergan, Sarah ;

Palumbo, Antonio ;

Lokhorst, Henk ;

Broijl, Annemiek ;

Sonneveld, Pieter .

HAEMATOLOGICA, 2019, 104 (11) :2265-2273

← 1 2 3 4 5 →